Stock COMBI COMBIGENE AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages CombiGene AB

Equities

COMBI

SE0016101935

Market Closed - Nasdaq Stockholm
Other stock markets
 17:00:00 28/06/2024 BST 		5-day change 1st Jan Change
2.9 SEK -5.23% Intraday chart for CombiGene AB -6.45% +7.81%
06-24 CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01 CI
05-27 CombiGene Appoints New Chief Scientific Officer MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01
CombiGene Appoints New Chief Scientific Officer
Combigene AB Appoints Annika Ericsson as New Chief Scientific Officer
CombiGene AB Approves Election of Marcus Isaksson as Board Member
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CombiGene Taps Charles River Laboratories as Clinical Research Partner for Pain Project
Combigene AB Chooses Charles River as Preclinical Toxicology Partner for COZY01 Pain Project
CombiGene AB and Zyneyro Choose Initial Indication in the Cozy01 Pain Project
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CombiGene AB Announces Chief Executive Officer Changes
Combigene AB to Play an Integrate Part in the Development of National Infrastructure for ATMPs
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2023
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
Combigene Enters into Collaboration Agreement with Zyneyro for the Development of A Unique Concept for Effective Relief of Chronic Pain
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COMBI Stock
  4. News CombiGene AB
  5. Other languages